Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures
Authors
Keywords
Apoptosis, Cell proliferation, Cancer stem cells, Cancer treatment, Mucin, Vimentin, Chemotherapy, MTS assay
Journal
PLoS One
Volume 10, Issue 11, Pages e0142124
Publisher
Public Library of Science (PLoS)
Online
2015-11-17
DOI
10.1371/journal.pone.0142124
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II trial of sorafenib (SOR) in patients (pts) with advanced cholangiocarcinoma (CC)
- (2017) C. Dealis et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiles of Cancer Stem Cell Subpopulations in Cholangiocarcinomas
- (2015) Vincenzo Cardinale et al. AMERICAN JOURNAL OF PATHOLOGY
- WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited
- (2015) Luke Boulter et al. JOURNAL OF CLINICAL INVESTIGATION
- Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
- (2015) Ming-Huang Chen et al. Oncotarget
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
- (2014) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The Prognostic Significance and Therapeutic Potential of Hedgehog Signaling in Intrahepatic Cholangiocellular Carcinoma
- (2013) L. Tang et al. CLINICAL CANCER RESEARCH
- Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma
- (2013) Florian Ewald et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer stem cells in the development of liver cancer
- (2013) Taro Yamashita et al. JOURNAL OF CLINICAL INVESTIGATION
- Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma
- (2013) Nataliya Razumilava et al. JOURNAL OF HEPATOLOGY
- Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
- (2013) J. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy
- (2013) Supak Yothaisong et al. TUMOR BIOLOGY
- Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance
- (2012) Alexander Levitzki Annual Review of Pharmacology and Toxicology
- Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
- (2012) Jeffrey A. Magee et al. CANCER CELL
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes
- (2012) Mina Komuta et al. HEPATOLOGY
- Inhibition of hedgehog signaling attenuates carcinogenesisin vitroand increases necrosis of cholangiocellular carcinoma
- (2012) Mona El Khatib et al. HEPATOLOGY
- Discrete nature of EpCAM+and CD90+cancer stem cells in human hepatocellular carcinoma
- (2012) Taro Yamashita et al. HEPATOLOGY
- Novel therapeutic Strategies for Targeting Liver Cancer Stem Cells
- (2012) Naoki Oishi et al. International Journal of Biological Sciences
- Dramatic Response to Trastuzumab and Paclitaxel in a Patient With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Cholangiocarcinoma
- (2012) Lisa Y. Law JOURNAL OF CLINICAL ONCOLOGY
- Hedgehog pathway as a drug target: Smoothened inhibitors in development
- (2012) Tara Lin et al. OncoTargets and Therapy
- Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity
- (2012) Vincenzo Cardinale World Journal of Gastrointestinal Oncology
- Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
- (2011) Jesper B. Andersen et al. GASTROENTEROLOGY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study
- (2011) Annekathrin Roth et al. ONKOLOGIE
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy
- (2010) Zichen Zhang et al. HEPATOLOGY
- Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
- (2010) Birgit Gruenberger et al. LANCET ONCOLOGY
- A limited role for dual EGFR and ErbB2 inhibition in cholangiocarcinoma?
- (2010) Shreeya Nanda Nature Reviews Gastroenterology & Hepatology
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search